Furthermore, like cytogenetic abnormalities, the number of driver mutations have independent prognostic impact in MDS which could be equivalent to that of TP53 mutations and which could allow identification of a subset of high-risk MDS patients with worse than expected survival outcomes. This evidence concerns the gene TP53 and myelodysplastic syndrome.